Details:
Mycapssa (octreotide) is an oral prescription medicine used in the long-term maintenance treatment of acromegaly in people for whom initial treatment with octreotide or lanreotide has been effective and tolerated.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
The study met its primary non-inferiority endpoint. 91% of patients on Mycapssa (octreotide) maintained insulin-like growth factor 1 (IGF-1) response (95% CI = 80%, 97%), throughout the RCT, compared to 100% on iSRLs (95% CI = 91%, 100%).
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The OPTIMAL study met the primary and all secondary endpoints which led to the US approval of Mycapssa (Octreotide), first oral somatostatin analog, for long-term maintenance treatment in acromegaly patients who tolerated treatment with injectable octreotide or lanreotide.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
The study achieved its objectives for Mycapssa® (octreotide capsules) and supports Phase 3 study in patients with carcinoid symptoms due to NET and results are consistent with prior PK study which was undertaken with these higher doses and compared to injectable SSA.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022